|
|
 Hydra's Ion Channel Advisors
 
David E. Clapham, M.D., Ph.D. Scientific Co-founder, Hydra Biosciences David Clapham is a leader in cell signal transduction, with particular expertise in ion channels and G protein-coupled receptors. As the Aldo R. Casteñada Professor of Cardiovascular Research at Children's Hospital of Boston, he is the hospital's director of Cardiovascular Research. He is also a professor of Neurobiology at Harvard Medical School, and a member of the American Academy of Arts and Sciences and the National Academy of Sciences. Early in his career, David established his independent research laboratory in the Department of Medicine at Brigham and Women's Hospital of Harvard Medical School. He earned an M.D. and Ph.D. in Anatomy/Cell Biology from Emory University School of Medicine and an Electrical Engineering degree at the Georgia Institute of Technology. David was a senior Fulbright Fellow during his postdoctoral training with Erwin Neher at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. Dr. Neher is the co-inventor (with B. Sakmann) of the patch clamp technique for which he won a Nobel Prize. 
Mark T. Keating, M.D. Scientific Co-Founder, Hydra Biosciences Mark Keating is a leader in the fields of regenerative biology medicine. He is Vice President of Human Genetics and Ophthalmology at Novartis, and adjunct professor of Cell Biology at Harvard Medical School, and adjunct professor of Cardiology at Children's Hospital of Boston. In 1989, Mark established his independent research laboratory in the department of Human Genetics at the University of Utah, the pioneer institution in human molecular genetics and mouse knockout technology, where his work initially focused on the human molecular genetics of cardiovascular disease and later extended to mechanisms of tissue and organ regeneration. He has received numerous awards for his laboratory's internationally recognized work in cardiovascular research including – the 2005 Bristol-Myers Squibs award for distinguished achievement in cardiovascular disease. He is a member of National Academy of Sciences. He earned his M.D. from The Johns Hopkins University School of Medicine and his bachelor's degree from Princeton University. 
Dean Y. Li, M.D., Ph.D. Scientific Co-Founder, Hydra Biosciences Dean Li is a leading researcher in defining mechanisms of vascular development and disease, including the effects of inadequate or undesirable vascular regeneration, and the development of novel therapies for vascular disease. He is an Associate Professor of Medicine in the departments of Oncological Sciences and Medicine at the University of Utah, and is a member of the Eccles Program of Human Molecular Biology and Genetics. Dean earned his M.D. and Ph.D. in Molecular Cell Biology at Washington University and his bachelor's degree from the University of Chicago. He is a Culpeper Medical Science Scholar, American Cancer Society Research Scholar, and director of the Vascular Biotherapeutics Center at the University of Utah, a Center of Excellence funded by the Utah Office of Technology Development. He is a member of the American Society of Clinical Investigations.
Michael Caterina, M.D., Ph.D. Associate Professor of Biological Chemistry and Neuroscience, Co-Director of the Biological Chemistry Graduate Program, Johns Hopkins School of Medicine. Michael Caterina is a sensory neurobiologist with a focus on the molecular basis of pain and temperature sensation. He is currently an Associate Professor of Biological Chemistry and Neuroscience, a member of the newly founded Center for Sensory Biology, and Co-Director of the Biological Chemistry Graduate Program at Johns Hopkins School of Medicine. Mike and his colleagues discovered the first heat-gated TRP channel, the capsaicin receptor TRPV1, and went on to identify a number of related heat-gated TRP channels that play diverse roles in temperature sensation as well as other sensory and nonsensory processes. His work has been recognized with a number of national and international awards, including the Patrick Wall Young Investigator Award from the International Association for the Study of Pain in 2005. Mike received M.D. and Ph.D. degrees from The Johns Hopkins School of Medicine, and prior to that earned his bachelor's degree from The Pennsylvania State University.  Sven-Eric Jordt, Ph.D. Associate Professor, Department of Pharmacology, Yale University School of Medicine
Marc Feldmann, M.D., Ph.D. Head of the Department of Cytokine Biology and the Kennedy Institute of Rheumatology Division, Imperial College London, UK Professor Feldmann is the Head of the Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London. He gained his MBBS (1967), BSc Med (Hons) (1970) and Ph.D. at the Walter & Eliza Hall Institute (with Sir Gus Nossal), all at the University of Melbourne (Australia) (1972). He went to London in 1972 to take up a postdoctoral position with Professor N.A. Mitchison at the Imperial Cancer Research Fund, University College Hospital (now Cancer Research UK). He joined the Sunley Research Centre in 1985 as the Deputy Director and Head of the Immunology Unit, which amalgamated with the Kennedy Institute of Rheumatology in 1992. His chief interest is the molecular pathogenesis of inflammatory and rheumatic disease, with a special interest in the role of cytokines in rheumatoid arthritis. His major accomplishment has been to discover the important role of TNFα in the pathogenesis of rheumatoid arthritis, this has led to the award, jointly with Professor Sir Ravinder Maini of the Crafoord Prize of the Royal Swedish Academy of Sciences in 2000 and the Albert Lasker Clinical Medical Research Award in 2003 for the discovery of anti-TNF therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases. 
David Julius, Ph.D. Professor, Department of Cellular & Molecular Pharmacology University of California, San Francisco David Julius is currently a Professor in the Department of Cellular & Molecular Pharmacology at the University of California, San Francisco. He is interested in the molecular biology of sensory transduction and neurotransmitter action in the mammalian nervous system. One of his goals is to understand the molecular basis of somatosensation - the process whereby we experience touch and temperature - with an emphasis on identifying molecules that detect noxious (pain-producing) stimuli. He is also interested in understanding how somatosensation is altered in response to tissue or nerve injury. David received his Ph.D. in Biochemistry from the University of California, Berkeley, and his bachelor's degree from the Massachusetts Institute of Technology. 
Mark Nelson, Ph.D. Professor and Chairman, Department of Pharmacology, University of Vermont College of Medicine Dr. Nelson is professor and chair of the Department of Pharmacology at University of Vermont, College of Medicine, where his lab is studying the control of smooth muscle cell function by the cell membrane. He is interested in examining the properties of calcium and potassium channels and ryanodine-sensitive calcium release channels. Calcium and potassium channels are the sites of action of several types of drugs that are used to treat cardiovascular disorders such as hypertension and angina. To understand the mechanism of action of these important drugs, the effects of these agents on calcium and potassium channel behavior are being investigated. Dr. Nelson is studying a combined approach utilizing single cell isolation, single channel and macroscopic recording techniques, intracellular calcium and calcium spark measurements using conventional fluorescent imaging techniques, laser scanning, and confocal microscopy, diameter and membrane potential measurements in intact pressurized arteries, and expression of ion channels. Dr. Nelson received his Ph.D. in Neural Sciences from Washington University, St. Louis, Missouri. 
Michael Sanguinetti, Ph.D. Professor of Physiology, University of Utah Michael Sanguinetti is currently a Professor of Physiology at the University of Utah, focusing on cardiac arrhythmias. Cardiac repolarization is dependent on activation of a surprisingly large number of potassium channels. Mutations in the genes encoding many of these channels cause inherited forms of cardiac arrhythmia. He uses site-directed mutagenesis of cloned channels and voltage clamp techniques to study the molecular basis of potassium channel dysfunction in these human disorders. In addition, he is exploring the molecular mechanisms that cause delayed rectifier and pacemaker channels to open and close in response to changes in transmembrane voltage. Dr. Sanguinetti received his Ph.D. from the University of California, Davis, and his bachelor's degree from Humboldt State University. 
Manfred Weigele, Ph.D. Chemistry Advisor Manfred Weigele, Ph.D., is a chemistry advisor with more than 40 years of experience in the pharmaceutical and biotechnology industry. Dr. Weigele obtained his Ph.D. in organic chemistry/biochemistry from the University of Wisconsin, Madison, in 1965. He then joined Hoffmann-La Roche in its Nutley, New Jersey, facility as a senior research scientist. At Hoffmann-La Roche, Dr. Weigele rose through the ranks to hold positions including group chief, section chief, and associate director of medicinal chemistry from 1971 to 1982; director of anti-infective chemistry from 1982 to 1983; director of medicinal chemistry from 1983 to 1985; and vice president and group director of chemistry research from 1985 to 1991. He retired from Roche in 1991 to participate in the founding of ARIAD Pharmaceuticals, a Cambridge, Massachusetts, biotech company dedicated to the structure-based design of drugs that intervene in critical intracellular signal transduction pathways. He retired from his position as senior vice president and chief scientific officer at ARIAD in 1999, but continues to retain a senior advisory role with the company. Dr. Weigele is co-author and/or co-inventor of over 150 scientific publications and U.S. patents. 
Clifford J. Woolf, M.D., Ph.D. Professor of Anesthesia Research, Harvard Medical School and Massachusetts General Hospital Dr. Woolf is the first incumbent of the Richard Kitz Chair of Anesthesia Research at Harvard Medical School and Massachusetts General Hospital. After training for his M.D. and Ph.D. at the University of the Witwatersrand in Johannesburg South Africa, Dr Woolf moved to England in 1978, where he worked at University College London for close on 20 years, latterly as a Professor of Neurobiology and as an Honorary Consultant at University College London Hospital. In 1997 Dr Woolf moved to Boston and established the Neural Plasticity Research Group based in the Department of Anesthesia and Critical Care at the Massachusetts General Hospital and which is a part of the Neuroscience Program at Harvard Medical School. |
 |
 |
 |
 |
Privacy Policy, Terms and Conditions • Hydra Biosciences, Inc. © 2006